174 related articles for article (PubMed ID: 32898246)
21. Use of four-factor prothrombin complex concentrate (4F-PCC) for management of bleeding not associated with therapeutic anticoagulant use.
Uttaro E; Young MR; Falvey J; Corvelli JM; Acquisto NM
Transfus Apher Sci; 2023 Oct; 62(5):103759. PubMed ID: 37453907
[TBL] [Abstract][Full Text] [Related]
22. Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis.
Abdoellakhan RA; Miah IP; Khorsand N; Meijer K; Jellema K
Neurocrit Care; 2017 Feb; 26(1):64-69. PubMed ID: 27052728
[TBL] [Abstract][Full Text] [Related]
23. An international, multicenter, prospective study of a prothrombin complex concentrate, Prothromplex Total®, in anticoagulant reversal.
Altorjay Á; Szabó É; Boda Z; Kramer L; Ngo LY; Engl W; Firth CL; Ahlstrom ER; Gelmont DM; Pabinger I
Thromb Res; 2015 Mar; 135(3):485-91. PubMed ID: 25613927
[TBL] [Abstract][Full Text] [Related]
24. Low-Dose Prothrombin Complex Concentrate in Patients with Left Ventricular Assist Devices.
Brown CS; Zemrak WR; Dyer KJ; Rolfe S
ASAIO J; 2019 Feb; 65(2):e21-e24. PubMed ID: 29561270
[TBL] [Abstract][Full Text] [Related]
25. Safety and Efficacy of Warfarin Reversal with Four-Factor Prothrombin Complex Concentrate for Subtherapeutic INR in Intracerebral Hemorrhage.
Rivosecchi RM; Durkin J; Okonkwo DO; Molyneaux BJ
Neurocrit Care; 2016 Dec; 25(3):359-364. PubMed ID: 27076286
[TBL] [Abstract][Full Text] [Related]
26. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation.
Yasaka M; Sakata T; Naritomi H; Minematsu K
Thromb Res; 2005; 115(6):455-9. PubMed ID: 15792675
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open-label, single-arm phase 3b study.
Kushimoto S; Fukuoka T; Kimura A; Toyoda K; Brainsky A; Harman A; Chung T; Yasaka M
Int J Hematol; 2017 Dec; 106(6):777-786. PubMed ID: 28815410
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
Kuroski JE; Young S
Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
[TBL] [Abstract][Full Text] [Related]
29. Weight-Based Dosing Versus a Fixed-Dose Regimen of 4-Factor Prothrombin Complex Concentrate in Obese Patients Requiring Vitamin K Antagonist Reversal.
Elsamadisi P; Cepeda MAG; Yankama T; Wong A; Tran Q; Eche IM
Am J Cardiovasc Drugs; 2021 May; 21(3):355-361. PubMed ID: 33150496
[TBL] [Abstract][Full Text] [Related]
30. Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0.
Zemrak WR; Smith KE; Rolfe SS; May T; Trowbridge RL; Hayes TL; Grindlinger GA; Seder DB
Neurocrit Care; 2017 Dec; 27(3):334-340. PubMed ID: 28660341
[TBL] [Abstract][Full Text] [Related]
31. A systematic review of prothrombin complex concentrate dosing strategies to reverse vitamin K antagonist therapy.
Khorsand N; Kooistra HA; van Hest RM; Veeger NJ; Meijer K
Thromb Res; 2015 Jan; 135(1):9-19. PubMed ID: 25480313
[TBL] [Abstract][Full Text] [Related]
32. Optimizing the dose of three-factor prothrombin complex concentrate in traumatic brain injury patients on warfarin therapy.
Huynh TK; Costello JL; Rebuck JA
Pharmacotherapy; 2014 Mar; 34(3):260-4. PubMed ID: 24338807
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Warfarin Reversal with 4-Factor Prothrombin Complex Concentrate Compared to 3-Factor Prothrombin Complex Concentrate at a Tertiary Academic Medical Center.
Al-Majzoub O; Rybak E; Reardon DP; Krause P; Connors JM
J Emerg Med; 2016 Jan; 50(1):7-13. PubMed ID: 26433428
[TBL] [Abstract][Full Text] [Related]
34. Comparison of 3 Different Prothrombin Complex Concentrate Regimens for Emergent Warfarin Reversal: PCCWaR Study.
Dietrich SK; Rowe S; Cocchio CA; Harmon AJ; Nerenberg SF; Blankenship PS
Ann Pharmacother; 2021 Aug; 55(8):980-987. PubMed ID: 33305592
[TBL] [Abstract][Full Text] [Related]
35. Study of Octaplex dosing accuracy: an in vitro analysis.
Patriquin CJ; Chin-Yee IH; Kovacs MJ; Lazo-Langner A; Keeney M; Hsia CC
Thromb Haemost; 2012 Feb; 107(2):248-52. PubMed ID: 22186847
[TBL] [Abstract][Full Text] [Related]
36. 3-Factor versus 4-Factor Prothrombin Complex Concentrates for the Reversal of Vitamin K Antagonist-Associated Coagulopathy: A Systematic Review and Meta-analysis.
Puchstein D; Kork F; Schöchl H; Rayatdoost F; Grottke O
Thromb Haemost; 2023 Jan; 123(1):40-53. PubMed ID: 36626899
[TBL] [Abstract][Full Text] [Related]
37. INR vs. thrombin generation assays for guiding VKA reversal: a retrospective comparison.
Herpers R; van Rossum AP; van Beem RT; Michel WM; Strijbis VJ; Strengers PF; Castel A; Brinkman HJ
Clin Chem Lab Med; 2015 Jul; 53(8):1227-36. PubMed ID: 25720079
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of fixed versus variable-dose prothrombin complex concentrate for emergent reversal of vitamin K antagonists: A systematic review and meta-analysis.
Condeni MS; Weant KA; Neyens RR; Eriksson EA; Miano TA
Am J Emerg Med; 2024 Mar; 77():91-105. PubMed ID: 38118388
[TBL] [Abstract][Full Text] [Related]
39. Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal.
Refaai MA; Goldstein JN; Lee ML; Durn BL; Milling TJ; Sarode R
Transfusion; 2015 Nov; 55(11):2722-9. PubMed ID: 26135740
[TBL] [Abstract][Full Text] [Related]
40. Adjusted versus actual body weight dosing of 4-factor prothrombin complex concentrate in obese patients with warfarin-associated major bleeding.
Smetana KS; Ziemba R; May CC; Erdman MJ; Van Matre ET; Jones GM
J Thromb Thrombolysis; 2019 Apr; 47(3):369-374. PubMed ID: 30460443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
